Insmed Valuation Multiples

Insmed Overview

About Insmed

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Founded

1999

HQ

Employees

1.7K

Website

insmed.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $933M

EBITDA: ($1B)

EV

$30B

Valuation Multiples

Multiples.vc

Start free trial

Insmed Financials

Insmed reported last 12-month revenue of $933M and negative EBITDA of ($1B).

In the same LTM period, Insmed generated $750M in gross profit, ($1B) in EBITDA losses, and had net loss of ($1B).

Insmed P&L

In the most recent fiscal year, Insmed reported revenue of $606M and EBITDA of ($1B).

Insmed expects next 12-month revenue of XXX and NTM EBITDA of XXX

Insmed Stock Performance

Insmed has current market cap of $31B, and enterprise value of $30B.

Insmed's stock price is $144.53.

Insmed Valuation Multiples

Insmed trades at 32.5x EV/Revenue multiple, and (29.9x) EV/EBITDA.

Insmed Financial Valuation Multiples

As of April 18, 2026, Insmed has market cap of $31B and EV of $30B.

Equity research analysts estimate Insmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Insmed has a P/E ratio of (29.4x).

Insmed Margins & Growth Rates

Insmed's revenue in the last 12 month grew by 119%.

Insmed's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.9M for the same period.

Insmed's rule of 40 is 152% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Insmed's rule of X is 426% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Insmed Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Insmed M&A Activity

Insmed acquired XXX companies to date.

Last acquisition by Insmed was on XXXXXXXX, XXXXX. Insmed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Insmed Investment Activity

Insmed invested in XXX companies to date.

Insmed made its latest investment on XXXXXXXX, XXXXX. Insmed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).